Skip to Main Content

Translational-Targeted Area of Research Excellence (T-TARE) Awards

The Yale Cancer Center T-TARE Program provides support of up to $200,000 for groups headed by a member of the Cancer Center, for research with a significant translational or clinical component, with the express purpose of developing a multi-investigator grant submission to the National Cancer Institute, such as a Program Project Grant or SPORE grant. The primary objectives of the T-TARE awards are to promote translational research and to facilitate collaborations between physicians and scientists. Consistent with these objectives, the review process of the proposals will be collaborative among physicians and scientists.

Review criteria:
1. Potential for project developing into a multi-investigator grant proposal within one year
2. Translational potential (overall and within three year time period)
3. Scientific merit/clinical feasibility
4. Strength of collaborative team (scientific strength, successful funding/publication record, commitment to clinical investigation, prior evidence of team interaction)
5. Strength of senior leadership (funding/publication track record)


For more information on the T-TARE Awards, please contact Anna Arnal Estapé, PhD.

Awards:

2022

Scalability study for Automated Clinical Trial Patient Matching System

Pamela Kunz, MD and Guannan Gong, PhD

$50,000

Mechanisms and Biomarkers for Combinatorial Treatment of Solid Tumors with BETi and HDACi

Qin Yan, PhD, and Patricia LoRusso, DO

$150,000

2021

A pilot study of interventions to increase adherence to cervical cancer early detection and treatment recommendations in Connecticut

Donna Spiegelman, ScD and Sangini Sheth, MD, MPH

$100,000

2020

CXCR5-targeted CAR-T for Aggressive T Cell Lymphomas

Elias Lolis, PhD, Samuel Katz, MD, PhD, Francine Foss, MD, and Jason Cai, PhD

$100,000

2019

Yale Brain SPORE Team

Murat Gunel, MD, and Antonio Omuro, MD

$150,000

Optimization of Cellular Immunotherapy for Melanoma

Marcus Bosenberg, MD, PhD, and Samuel Katz, MD, PhD

$100,000

2016

Novel therapies and targets in head and neck cancer

Barbara Burtness, MD

$200,000

DNA repair as a target for cancer therapies

Patricia LoRusso, DO and Joann Sweasy, PhD

$200,000

2013

Expanding Therapeutic Options for Triple Negative Breast Cancer

Lajos Pusztai, MD, DPhil

$140,000

Divide and Conquer: Advancing Therapy for Head and Neck Squamous Cell Carcinoma

Wendell Yarbrough, MD

$125,000

Next Generation Targeting of Oncogenes in the Tumor Microenvironment

Frank Slack, PhD

$160,000

2012

The biology and treatment of primary and metastatic lung cancer

Roy S. Herbst, MD, PhD

$200,000

Comprehensive approaches for understanding and treating melanoma brain metastases

Harriet Kluger, MD

$150,000

Translation of convection-enhanced delivery of drug-loaded nanoparticles for treatment of glioma

W. Mark Saltzman, PhD and Joseph Piepmeier, MD

$130,000